UY37676A - Tratamiento para el asma con anticuerpo anti-tslp - Google Patents

Tratamiento para el asma con anticuerpo anti-tslp

Info

Publication number
UY37676A
UY37676A UY0001037676A UY37676A UY37676A UY 37676 A UY37676 A UY 37676A UY 0001037676 A UY0001037676 A UY 0001037676A UY 37676 A UY37676 A UY 37676A UY 37676 A UY37676 A UY 37676A
Authority
UY
Uruguay
Prior art keywords
asthma
treatment
tslp antibody
tslp
antibody
Prior art date
Application number
UY0001037676A
Other languages
English (en)
Spanish (es)
Inventor
R Parnes Jane
Janet Griffiths
Original Assignee
Amgen Inc
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Medimmune Llc filed Critical Amgen Inc
Publication of UY37676A publication Critical patent/UY37676A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001037676A 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp UY37676A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01

Publications (1)

Publication Number Publication Date
UY37676A true UY37676A (es) 2018-10-31

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037676A UY37676A (es) 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp

Country Status (21)

Country Link
US (3) US10828365B2 (OSRAM)
EP (1) EP3609917A1 (OSRAM)
JP (4) JP7330896B2 (OSRAM)
KR (2) KR20240070727A (OSRAM)
CN (1) CN110573525A (OSRAM)
AU (2) AU2018253118B2 (OSRAM)
BR (1) BR112019021482A2 (OSRAM)
CA (1) CA3059364A1 (OSRAM)
CL (1) CL2019002897A1 (OSRAM)
CO (1) CO2019011462A2 (OSRAM)
IL (1) IL269791B (OSRAM)
JO (1) JOP20190243A1 (OSRAM)
MX (1) MX2019012158A (OSRAM)
MY (1) MY207509A (OSRAM)
PE (1) PE20200484A1 (OSRAM)
PH (1) PH12019502331A1 (OSRAM)
SG (1) SG11201909322VA (OSRAM)
TN (1) TN2019000289A1 (OSRAM)
TW (2) TWI856945B (OSRAM)
UY (1) UY37676A (OSRAM)
WO (1) WO2018191479A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61763B1 (sr) * 2015-09-09 2021-05-31 Novartis Ag Antitela koja vezuju timusni stromalni limfopoetin (tslp) i metode za korišćenje antitela
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
WO2020244544A1 (zh) * 2019-06-04 2020-12-10 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
CN117467007A (zh) * 2019-09-04 2024-01-30 正大天晴药业集团股份有限公司 结合tslp的抗体及其用途
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
KR20220113673A (ko) * 2019-12-13 2022-08-16 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-tslp 항체 및 그 용도
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US20230073888A1 (en) * 2020-02-13 2023-03-09 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
IL295042A (en) * 2020-02-13 2022-09-01 Amgen Inc Formulations of human anti-tslp antibodies and methods of treating inflammatory disease
AR121368A1 (es) * 2020-02-18 2022-06-01 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
WO2022184074A1 (zh) * 2021-03-03 2022-09-09 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
PH12023552762A1 (en) * 2021-04-19 2024-04-15 Medimmune Ltd An anti-tslp fab with improved stability
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
MX2023012363A (es) 2021-04-23 2023-11-01 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas.
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
AR133648A1 (es) * 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos anti-tslp y sus usos
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
SG11201700901SA (en) * 2014-08-08 2017-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
AU2016231122A1 (en) 2015-03-11 2017-09-07 Glaxosmithkline Intellectual Property Development Limited TSLP binding proteins
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Also Published As

Publication number Publication date
CN110573525A (zh) 2019-12-13
CO2019011462A2 (es) 2019-10-31
IL269791A (en) 2019-11-28
KR102666879B1 (ko) 2024-05-23
AU2018253118B2 (en) 2025-04-10
MX2019012158A (es) 2019-12-16
TW202523688A (zh) 2025-06-16
TWI856945B (zh) 2024-10-01
AU2018253118A1 (en) 2019-10-24
SG11201909322VA (en) 2019-11-28
TW201838652A (zh) 2018-11-01
JP7330896B2 (ja) 2023-08-22
JOP20190243A1 (ar) 2019-10-13
US10828365B2 (en) 2020-11-10
CL2019002897A1 (es) 2020-03-06
IL269791B (en) 2022-07-01
JP2024150751A (ja) 2024-10-23
CA3059364A1 (en) 2018-10-18
MY207509A (en) 2025-02-28
TN2019000289A1 (en) 2021-05-07
JP2020516647A (ja) 2020-06-11
KR20190140956A (ko) 2019-12-20
JP2023099233A (ja) 2023-07-11
BR112019021482A2 (pt) 2020-05-12
JP2025170430A (ja) 2025-11-18
AU2025204735A1 (en) 2025-07-17
US20180296669A1 (en) 2018-10-18
KR20240070727A (ko) 2024-05-21
WO2018191479A1 (en) 2018-10-18
US20210052726A1 (en) 2021-02-25
PE20200484A1 (es) 2020-03-03
EP3609917A1 (en) 2020-02-19
PH12019502331A1 (en) 2020-09-28
US20250032608A1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
CO2019011462A2 (es) Tratamiento para el asma con anticuerpo anti-tslp
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
MX387159B (es) Moléculas basadas en il-15 y métodos para su uso.
MX2018016078A (es) Composiciones que comprenden cepas bacterianas.
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
CO2017000300A2 (es) Moléculas con especificidad para cd45 y cd79
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
BR112017014230A2 (pt) endófitos de semente através de cultivares e espécies, composições associadas e métodos de uso dos mesmos
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2023003432A1 (es) Fragmento de union fab de igg1 del anticuerpo anti-tslp
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
MX2017012834A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
UY37091A (es) Cepas fúngicas solubilizantes de fosfato
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
CL2018003167A1 (es) Selección de cepas bacterianas útiles en el tratamiento de alergias.
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20241209